Compare SPCE & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | WHWK |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5M | 179.8M |
| IPO Year | 2017 | N/A |
| Metric | SPCE | WHWK |
|---|---|---|
| Price | $2.92 | $3.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $3.26 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 4.8M | 172.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,544,000.00 | N/A |
| Revenue This Year | $2,766.13 | N/A |
| Revenue Next Year | $699.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $1.39 |
| 52 Week High | $5.59 | $4.40 |
| Indicator | SPCE | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 47.71 |
| Support Level | $2.91 | $1.84 |
| Resistance Level | $3.42 | $3.77 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 83.82 | 32.53 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.